These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17436552)

  • 1. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy.
    Nilsson FY; Tolmachev V
    Curr Opin Drug Discov Devel; 2007 Mar; 10(2):167-75. PubMed ID: 17436552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular imaging in cancer.
    Weissleder R
    Science; 2006 May; 312(5777):1168-71. PubMed ID: 16728630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
    Tran T; Engfeldt T; Orlova A; Sandström M; Feldwisch J; Abrahmsén L; Wennborg A; Tolmachev V; Karlström AE
    Bioconjug Chem; 2007; 18(6):1956-64. PubMed ID: 17944527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody.
    Mume E; Orlova A; Larsson B; Nilsson AS; Nilsson FY; Sjöberg S; Tolmachev V
    Bioconjug Chem; 2005; 16(6):1547-55. PubMed ID: 16287254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered affinity proteins for tumour-targeting applications.
    Friedman M; Ståhl S
    Biotechnol Appl Biochem; 2009 May; 53(Pt 1):1-29. PubMed ID: 19341363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules.
    Tran TA; Ekblad T; Orlova A; Sandström M; Feldwisch J; Wennborg A; Abrahmsén L; Tolmachev V; Eriksson Karlström A
    Bioconjug Chem; 2008 Dec; 19(12):2568-76. PubMed ID: 19035668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand.
    Tran T; Orlova A; Sivaev I; Sandström M; Tolmachev V
    Int J Mol Med; 2007 Mar; 19(3):485-93. PubMed ID: 17273798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor.
    Friedman M; Nordberg E; Höidén-Guthenberg I; Brismar H; Adams GP; Nilsson FY; Carlsson J; Ståhl S
    Protein Eng Des Sel; 2007 Apr; 20(4):189-99. PubMed ID: 17452435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multifunctional nanostructured materials for multimodal imaging, and simultaneous imaging and therapy.
    Kim J; Piao Y; Hyeon T
    Chem Soc Rev; 2009 Feb; 38(2):372-90. PubMed ID: 19169455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide-based molecular beacons for cancer imaging and therapy.
    Liu TW; Chen J; Zheng G
    Amino Acids; 2011 Nov; 41(5):1123-34. PubMed ID: 20169374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold.
    Nygren PA
    FEBS J; 2008 Jun; 275(11):2668-76. PubMed ID: 18435759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule.
    Friedman M; Orlova A; Johansson E; Eriksson TL; Höidén-Guthenberg I; Tolmachev V; Nilsson FY; Ståhl S
    J Mol Biol; 2008 Mar; 376(5):1388-402. PubMed ID: 18207161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy.
    Pantaleo MA; Nannini M; Maleddu A; Fanti S; Ambrosini V; Nanni C; Boschi S; Biasco G
    Cancer Treat Rev; 2008 Apr; 34(2):103-21. PubMed ID: 18055120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and chemoselective intramolecular crosslinking of a HER2-binding affibody.
    Ekblad T; Tolmachev V; Orlova A; Lendel C; Abrahmsén L; Karlström AE
    Biopolymers; 2009; 92(2):116-23. PubMed ID: 19140162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules.
    Ekblad T; Orlova A; Feldwisch J; Wennborg A; Karlström AE; Tolmachev V
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3912-4. PubMed ID: 19364646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular-genetic imaging based on reporter gene expression.
    Kang JH; Chung JK
    J Nucl Med; 2008 Jun; 49 Suppl 2():164S-79S. PubMed ID: 18523072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phage peptide display.
    Newton J; Deutscher SL
    Handb Exp Pharmacol; 2008; (185 Pt 2):145-63. PubMed ID: 18626602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small animal PET in preclinical studies: opportunities and challenges.
    Riemann B; Schäfers KP; Schober O; Schäfers M
    Q J Nucl Med Mol Imaging; 2008 Sep; 52(3):215-21. PubMed ID: 18551093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiopharmaceuticals: molecular imaging using positron emission tomography.
    Antoni G; Långström B
    Handb Exp Pharmacol; 2008; (185 Pt 1):177-201. PubMed ID: 18626804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor-mediated tumor targeting with radiopeptides. Part 1. General principles and methods.
    Eberle AN; Mild G
    J Recept Signal Transduct Res; 2009; 29(1):1-37. PubMed ID: 19519167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.